Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ: CMPS )

3.490 -0.240 (-6.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2
...
22 23 24 25 26 27 28 29 Next >
Analyzing Compass Pathways's Unusual Options Activity
On Wednesday, shares of Compass Pathways (NASDAQ:CMPS) sa... 
Via Benzinga
Analyzing Compass Pathways's Unusual Options Activity
Shares of Compass Pathways (NASDAQ:CMPS) saw some unusual... 
Via Benzinga
Which Psychedelic Drug Has The Most Commercial Potential?
As the Mental Health Crisis has become a mental health pandemic, clinical research on psychedelic drugs is showing that these substances are the best – and only – option to address this crisis. 
Via Talk Markets
Cybin Becomes First Psychedelics Company On The NYSE: CEO Explains Everything You Need To Know
Cybin (NYSE:CYBN), a biotech company in the psychedelics spa... 
Via Benzinga
Growing Psychedelic Interest Will Help Push Compass Pathways Stock Up 3X By 2022
Psychedelic stock headwinds are improving, and since Compass is at the forefront of psychedelic therapy, look for CMPS stock to take off soon. 
Via InvestorPlace
Another Psychedelic Stock Debuts, As This One Sets Up In A Base
Field Trip Health dipped in its first day on the Nasdaq, making it the latest psychedelics company to hit a big U.S. exchange. 
Via Investor's Business Daily
Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To "Psychedelics Renaissance"
Excitement around psychedelics grows as major U.S. exchanges make room for more companies in the sector. On Friday, 
Via Benzinga
Post-COVID Investment Mega-Opportunity: Mental Health And Psychedelic Drug Stocks
After governments have obsessed for the past 18 months about COVID-19, they are now forced to confront a much larger pandemic: the Mental Health Pandemic. This enormous crisis is also a huge investing... 
Via Talk Markets
Exposures COVID-19
Psychedelic Decriminalization Creating Market Opportunities
Via FinancialNewsMedia
Topics Cannabis Law Enforcement
Exposures Cannabis Legal
How To Invest In "Magic Mushrooms" (Psychedelics)
A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021
Upgrades For Royal Dutch Shell PLC (NYSE:RDS), Bar... 
Via Benzinga
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Ps... 
Via Benzinga
The 6 Leading Psychedelic Stocks In Drug R&D
Drug R&D in the emerging psychedelic drug industry continues to advance. Share prices continue to lag. Here's a comparison of the strengths and weaknesses of six of the leaders in psychedelic drug R&D... 
Via Talk Markets
Rising Prevalence of Mental Depression & Anxiety Major Drivers Propelling Demand In Psychedelic Drugs Market
Via FinancialNewsMedia
Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential o... 
Via Benzinga
Understanding Compass Pathways's Unusual Options Activity
On Thursday, shares of Compass Pathways (NASDAQ:CMPS) saw unusual options activity. After the option alert, the stock price moved up to $38.2. Sentiment: NEUTRAL Option Type:... 
Via Benzinga
Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More
Institutional analysts are taking a liking to the industry ... 
Via Benzinga
3 Top Psychedelic Stocks to Buy Now
These companies developing hallucinogens have more than meets the eye. 
Via The Motley Fool
Compass Pathways Completes Target Administration Of Psilocybin Therapy In World's Largest Study
Compass Pathways (NASDAQ:CMPS), a biotech company in the p... 
Via Benzinga
Pandemic Fallout: 6 Mental Health Stocks To Watch
One of the most devastating long-term impacts of the COVID-19 pandemic may be the toll it has taken on people’s mental health. The next globa... 
Via Benzinga
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2021
Upgrades For Toll Brothers Inc (NYSE: 
Via Benzinga
Atai IPO Day An Underwhelming Event
The IPO of atai Life Sciences was arguably the most-anticipated event in the emerging psychedelic drug industry. It failed to live up to expectations. 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform
Atai Life Sciences (NASDAQ: ATAI) made its highly-anticipated Nasdaq... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Peter Thiel-backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public
Atai Life Sciences (NASDAQ:ATAI), a biotech company in the... 
Via Benzinga
New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End
Atai Life Sciences, a backer of psychedelic-drug developers, will start trading Friday, after an upsized offering for the Atai IPO. 
Via Investor's Business Daily
Topics Initial Public Offering
Exposures Securities Market
Is ATAI Stock A Buy After The IPO?
ATAI Life Sciences will go public this week. And investors wanting to cash in on one of the hottest medicine and mental health trends need to pay attention to this stock. 
Via Talk Markets
Here's How This Psychedelic Drug CEO Sees The Industry Evolving
Competition within legal psychedelic drugs has only barely taken shape. Companies focused on therapy will be the ultimate winners, one CEO said. 
Via Investor's Business Daily
What Do You Really Know About Psychedelics And Psychedelics Stocks?
According to a new poll conducted by Hill-HarrisX, 65% of registered voters say psychedelic substances do not have medical use. That... 
Via Benzinga
Why the North America Psychedelic Drugs Market is Expected to Grow With the Fastest CAGR for Next Several Years
Via FinancialNewsMedia
Topics Law Enforcement
Exposures Legal
Psyched: First Psychedelics ETF Comes To The US, Bills Move Forward In Texas, California and New York
Psychedelics ETFs Are Gaining Traction Defiance ETFs launched the “Next Gen Altered Experience ETF,” the ... 
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.